We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Escape Velocity—the Launch of Microbiome Therapies.
- Authors
Kelly, Brendan J; Kwon, Jennie H; Woodworth, Michael H
- Abstract
Food and Drug Administration approval of the first microbiome therapies represents a true expansion the treatment paradigm for Clostridioides difficile but raises new questions about the future role of fecal microbiota transplantation. The authors outline the advances in microbiome therapeutic development that have addressed fecal microbiota transplantation's (FMT's) inherent limitations of safety and scalability. The authors also suggest that as microbiome therapeutic development continues for other indications, FMT will likely remain a necessary model of human microbiota dynamics for translational research.
- Subjects
UNITED States. Food &; Drug Administration; FECAL microbiota transplantation; CLOSTRIDIOIDES difficile; HUMAN microbiota; DRUG approval; TRANSLATIONAL research
- Publication
Journal of Infectious Diseases, 2024, Vol 230, Issue 1, p2
- ISSN
0022-1899
- Publication type
Article
- DOI
10.1093/infdis/jiae099